Saladax Biomedical
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
N/A | N/A | Seed | |
N/A | $3.5m | Early VC | |
$3.6m | Series A | ||
$7.9m | Series B | ||
$8.4m | Series C | ||
$9.0m | Debt | ||
$22.4m | Growth Equity VC | ||
$100k | Grant | ||
* | $200k | Grant | |
Total Funding | $46.1m |
Recent News about Saladax Biomedical
EditSaladax Biomedical specializes in developing rapid blood tests aimed at enhancing personalized medicine for psychiatrists, oncologists, and neurologists. Operating in the healthcare diagnostics market, Saladax provides laboratories worldwide with innovative diagnostic solutions that ensure reliable and swift diagnosis. The company’s business model revolves around creating and supplying high-quality assays that enable personalized dosing, ensuring that the right drug is administered at the right dose for each unique patient. By focusing on the areas of Psychiatry, Oncology, and Neurology, Saladax addresses the critical need for precision medicine, thereby improving patient outcomes and healthcare efficiency. Revenue is generated through the sale of these diagnostic tests to laboratories and healthcare providers globally.
Keywords: personalized medicine, rapid blood tests, psychiatry, oncology, neurology, diagnostic solutions, precision medicine, assays, healthcare diagnostics, patient outcomes.